Pliant Therapeutics is no longer a fibrosis company. After the BEACON-IPF program was stopped on an unfavorable risk-benefit read, the South San Francisco integrin shop cut the workforce, repaid its term loan, and recentered the equity on a single oral oncology candidate designed to reopen checkpoint-resistant tumors. The market now values the common below the cash on the balance sheet, which is the entire investment argument in one line: either the residual oncology option is being given away, or the cash is already spoken for by a trial that has not yet produced a controlled signal.
The second-quarter print is the first clean look at the post-fibrosis cost base. Research spending fell to $17 million. The net loss compressed to $22 million. That is not operating leverage from a growing franchise. It is the arithmetic of shutting a late-stage idiopathic pulmonary fibrosis study and running a much smaller oncology shop. Cash and short-term investments still sit near $160 million. Management's stated plan funds operations into late 2028, which is after the FORTIFY interim.
The clinical case still rests on a tiny Phase One cohort: a handful of confirmed responses in heavily pretreated checkpoint-refractory patients, plus an interferon-gamma split that separated responders from non-responders before pembrolizumab was even added. Fast Track designation arrived in mid-August for the combination, and FORTIFY enrollment is running ahead of the original pace. The question the next year actually resolves is whether those early responses repeat in defined cohorts of lung cancer, kidney cancer, and high-mutation tumors, or whether the market is right to treat the cash as a wasting asset against a signal that does not scale.